SIGNAL Huntington’s Disease Trial (VX15-2503-N-131): Cohort B Topline Results
Learnings from SIGNAL Phase 2 Study
ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: CLASSICAL-Lung Combination Trial of Pepinemab with Avelumab
ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: Antibody Blockade of Semaphorin 4D Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade
Poster: 2020 Head and Neck Cancers Symposium. “Integrated Biomarker Study of Pepinemab in Combination With Ipilimumab or Nivolumab to Evaluate Immune Cell Composition of TME in Patients With Head And Neck Squamous Cell Carcinoma and Other Solid Tumors”
Poster: 2020 HD Therapeutics Conference Sponsored by CHDI. “Pepinemab, an anti-semaphorin 4D blocking antibody as a potential treatment for neurodegenerative disease: Treatment rationale and SIGNAL HD and AD trial updates.”
Virtual Presentation at the “Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD™ Focus Meeting 2020”
Audio / Visual Presentation: Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
ASCO Presentation: Abstract #3011 Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.